Basel, Switz\u00ader\u00adland \/ Munich, Germany \u2014 NUCLIDIUM, a clini\u00adcal-stage radio\u00adphar\u00admaceu\u00adti\u00adcal company deve\u00adlo\u00adping a proprie\u00adtary copper-based ther\u00adano\u00adstic plat\u00adform, announ\u00adced the closing of its Series B finan\u00adcing round of CHF 79 million (EUR 84 million). The round was led by Kurma Growth Oppor\u00adtu\u00adni\u00adties Fund, Ange\u00adlini Ventures, Welling\u00adton Part\u00adners and Neva SGR (Intesa Sanpaolo Group), with parti\u00adci\u00adpa\u00adtion from DeepT\u00adech & Climate Fonds (DTCF), Bayern Kapi\u00adtal, Vives Part\u00adners, Eura\u00adzeo, NRW.BANK and High\u00adLight Capi\u00adtal, as well as exis\u00adting investors. <\/p>\n
The proceeds will be used to advance the clini\u00adcal deve\u00adlo\u00adp\u00adment of NUCLI\u00adDI\u00adUM\u2019s copper-61\/cop\u00adper-67 (61Cu\/67Cu) ther\u00adano\u00adstic pipe\u00adline in various onco\u00adlogy indi\u00adca\u00adti\u00adons. In paral\u00adlel, the company will expand its produc\u00adtion and manu\u00adfac\u00adtu\u00adring capa\u00adbi\u00adli\u00adties through a global manu\u00adfac\u00adtu\u00adring network. <\/p>\n
NUCLI\u00adDI\u00adUM\u2019s diffe\u00adren\u00adtia\u00adted plat\u00adform combi\u00adnes tumor-targe\u00adting mole\u00adcu\u00adles with copper isoto\u00adpes \u2014 copper-61 for diagno\u00adstics and copper-67 for therapy \u2014 to over\u00adcome current limi\u00adta\u00adti\u00adons in radio\u00adther\u00adano\u00adstics, such as subop\u00adti\u00admal clini\u00adcal effi\u00adcacy and manu\u00adfac\u00adtu\u00adring comple\u00adxity. Diagno\u00adstic results from initial clini\u00adcal studies in these indi\u00adca\u00adti\u00adons show better lesion detec\u00adtion and tumor-to-back\u00adground ratios compared to clini\u00adcally appro\u00adved tracers. Initial data was recently presen\u00adted at SNMMI 2025 by Dr. Gary Ulaner, MD, PhD, demons\u00adt\u00adra\u00adting a favorable safety profile and poten\u00adti\u00adally impro\u00adved imaging perfor\u00admance of 61Cu-Nuri\u00adPro\u2122 compared to current PET imaging stan\u00addards, suggest\u00ading great clini\u00adcal poten\u00adtial and broa\u00adder poten\u00adtial for the ther\u00adano\u00adstic pairing of 61Cu\/67Cu. Early thera\u00adpeu\u00adtic data from the two lead compounds Nuri\u00adPro\u2122 and Trace\u00adNET\u2122 show good tumor-to-back\u00adground ratios in meta\u00adsta\u00adtic prostate cancer and neuro\u00aden\u00addo\u00adcrine tumors, inclu\u00adding breast cancer. <\/p>\n
\u201cNUCLIDIUM is ente\u00adring the next clini\u00adcal phases with its compounds for the diagno\u00adsis and treat\u00adment of meta\u00adsta\u00adtic prostate cancer, neuro\u00aden\u00addo\u00adcrine tumors and breast cancer,\u201d said Leila Jaafar, PhD, CEO and co-foun\u00adder of NUCLIDIUM<\/strong>. \u201cOur copper-based radio\u00adther\u00adano\u00adstics are desi\u00adgned for seam\u00adless use in hospi\u00adtal work\u00adflows, care and waste manage\u00adment, making these thera\u00adpies more acces\u00adsi\u00adble worldwide.\u201d <\/p>\n With this finan\u00adcing, NUCLIDIUM will further expand its global produc\u00adtion and manu\u00adfac\u00adtu\u00adring network for diagno\u00adstics and thera\u00adpeu\u00adtics, grow its inter\u00adna\u00adtio\u00adnal team and streng\u00adthen its stra\u00adte\u00adgic colla\u00adbo\u00adra\u00adtion with hospi\u00adtals and acade\u00admic centers, initi\u00adally in Europe and North America.<\/p>\n In connec\u00adtion with the finan\u00adcing round, Dr. Daniel Parera, Part\u00adner at Kurma Part\u00adners, Dr. Regina Hodits, Mana\u00adging Direc\u00adtor at Ange\u00adlini Ventures, and Liliana Nord\u00adbakk, Life Scien\u00adces Part\u00adner at Neva SGR, will join the Board of Direc\u00adtors of NUCLIDIUM.<\/p>\n Consul\u00adtant NUCLIDIUM:<\/strong><\/p>\n The Series B finan\u00adcing was supported by VISCHER AG and Walder Wyss, Switz\u00ader\u00adland, as legal advisors.<\/p>\n About NUCLIDIUM The company\u2019s opera\u00adti\u00adons in Switz\u00ader\u00adland and Germany combine inno\u00adva\u00adtive chemis\u00adtry, deep clini\u00adcal exper\u00adtise and stra\u00adte\u00adgic manu\u00adfac\u00adtu\u00adring capa\u00adbi\u00adli\u00adties to provide scalable, acces\u00adsi\u00adble and clini\u00adcally supe\u00adrior ther\u00adano\u00adstic solu\u00adti\u00adons to pati\u00adents world\u00adwide. NUCLI\u00adDI\u00adUM\u2019s mission is to increase the reach and effi\u00adcacy of radio\u00adther\u00adano\u00adstics while addres\u00adsing criti\u00adcal unmet medi\u00adcal needs in onco\u00adlogy and women\u2019s health.<\/p>\n
\n<\/strong>
\n NUCLIDIUM AG is a clini\u00adcal-stage biotech\u00adno\u00adlogy company pionee\u00adring the deve\u00adlo\u00adp\u00adment of next-gene\u00adra\u00adtion copper-based radio\u00adphar\u00admaceu\u00adti\u00adcals for the diagno\u00adsis and treat\u00adment of cancer. Through the use of copper isoto\u00adpes \u2014 copper-61 for diagno\u00adstics and copper-67 for therapy \u2014 NUCLIDIUM is crea\u00adting a diffe\u00adren\u00adtia\u00adted plat\u00adform that has the poten\u00adtial to over\u00adcome exis\u00adting limi\u00adta\u00adti\u00adons in radiotheranostics. <\/p>\n